Company Provectus Pharmaceuticals, Inc. OTC Bulletin Board
Equities
PVCT
US74373F1003
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Immunotherapy Medicines
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -43.61% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | -43.61% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Edward Pershing
CEO | Chief Executive Officer | 70 | 18-04-26 |
Eric Wachter
FOU | Founder | 60 | 02-03-31 |
Heather Raines
DFI | Director of Finance/CFO | 57 | 17-07-31 |
President | 55 | 17-04-02 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Wachter
FOU | Founder | 60 | 02-03-31 |
John Lacey
BRD | Director/Board Member | 76 | 18-04-26 |
President | 55 | 17-04-02 | |
Edward Pershing
CEO | Chief Executive Officer | 70 | 18-04-26 |
Webster Bailey
BRD | Director/Board Member | 47 | 20-07-19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 10,587,571 | 0 | 0 | 91.94 % |
Stock B | 0 | 12,373,247 | 0 | 0 | |
Stock C | 1 | 419,522,119 | 385,696,228 ( 91.94 %) | 0 |
Company contact information
Provectus Biopharmaceuticals, Inc.
800 South Gay Street Suite 1610
37929, Knoxville
+866 594 5999
http://www.provectusbio.com![address Provectus Pharmaceuticals, Inc.(PVCT)](https://cdn.zonebourse.com/static/address/77765.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+19.44% | 124B | |
+20.01% | 114B | |
+21.11% | 25.83B | |
-23.72% | 19.42B | |
-18.17% | 16.2B | |
-19.87% | 15.31B | |
+55.81% | 14.32B | |
+8.76% | 14.31B | |
-48.79% | 14.19B |
- Stock Market
- Equities
- PVCT Stock
- PVCT Stock
- Company Provectus Pharmaceuticals, Inc.